Calcilytix Therapeutics

www.calcilytix.com

Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.

Read more

Reach decision makers at Calcilytix Therapeutics

Lusha Magic

Free credit every month!

Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.

Read more
icon

Country

icon

State

California

icon

City (Headquarters)

San Francisco

icon

Employees

11-50

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Senior Vice President , Corporate Development

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Medical Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Director

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(3)

Reach decision makers at Calcilytix Therapeutics

Free credits every month!

My account

Sign up now to uncover all the contact details